|
|
Article: CREON pancrelipase Delayed-Release Capsules Improves Digestive Outcomes In Adults With Chronic Pancreatitis.
- Article from:
- Gene Therapy Weekly
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Solvay Pharmaceuticals, Inc. announced that new data demonstrate that CREON[R] (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery. EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food and, if untreated, can lead to diarrhea, weight loss and ultimately malnutrition (see also Solvay Pharmaceuticals, Inc.).
Findings from this Phase III study, which have been submitted to the FDA, were presented at the American College ...